Navigation Links
Inovio Pharmaceuticals' Market-Leading Intellectual Property Recognized by MDB Capital Award
Date:5/12/2011

rams (including, but not limited to, the fact that pre-clinical and clinical results referenced in this release may not be indicative of results achievable in other trials or for other indications, that the studies or trials may not be successful or achieve the results desired, that results from one study may not necessarily be reflected or supported by the results of other similar studies and that results from an animal study may not be indicative of results achievable in human studies), the availability of funding to support continuing research and studies in an effort to prove safety and efficacy of electroporation technology as a delivery mechanism or develop viable DNA vaccines, the adequacy of our capital resources, the availability or potential availability of alternative therapies or treatments for the conditions targeted by the company or its collaborators, including alternatives that may be more efficacious or cost-effective than any therapy or treatment that the company and its collaborators hope to develop, evaluation of potential opportunities, issues involving product liability, issues involving patents and whether they or licenses to them will provide the company with meaningful protection from others using the covered technologies, whether such proprietary rights are enforceable or defensible or infringe or allegedly infringe on rights of others or can withstand claims of invalidity and whether the company can finance or devote other significant resources that may be necessary to prosecute, protect or defend them, the level of corporate expenditures, assessments of the company's technology by potential corporate or other partners or collaborators, capital market conditions, our ability to successfully integrate Inovio and VGX Pharmaceuticals, the impact of government healthcare proposals and other factors set forth in our Annual Report on Form 10-K for the year ended December 31, 2010, our Form 10-Q for the three months ended March 3
'/>"/>

SOURCE Inovio Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Inovio Pharmaceuticals to Present at Investor Conferences
2. Inovio Pharmaceuticals, Transgene and ChronTech Pharma to Collaborate on Heterologous Prime-Boost Therapeutic Vaccination Against Hepatitis C
3. OncoSec Medical Closes Purchase and License Agreement for Tumor Therapy Technology with Inovio Pharmaceuticals
4. Inovio Pharmaceuticals to Present at Scientific Conferences
5. Inovio Pharmaceuticals Receives U.S. DOD Small Business Innovation Research Grant for Multi-Vaccine DNA Delivery Device Development
6. Inovio Pharmaceuticals Reports 2010 Fourth Quarter and Year End Financial Results
7. Inovio Pharmaceuticals Licenses Non-DNA Vaccine Tumor Therapy Technology to OncoSec Medical
8. OncoSec Medical Licenses Non-DNA Vaccine Tumor Therapy Technology from Inovio Pharmaceuticals
9. Inovio Pharmaceuticals Partner ChronTech Initiates Phase II Clinical Trial of Hepatitis C Virus DNA Vaccine Using Inovios Electroporation Delivery Technology
10. Inovio Pharmaceuticals to Present at ROTH 23rd Annual Growth Stock Conference
11. Inovio Pharmaceuticals to Present at Cowen & Co. Health Care Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 2014 Most osteoporosis patients want a choice in ... survey* sponsored by Mission Pharmacal Company. The survey, conducted ... online support community, revealed that 74 percent of osteoporosis ... a form other than a pill or a tablet. ...
(Date:1/15/2014)... LAWRENCEVILLE, N.J. , Jan. 15, 2014  Celsion Corporation (the ... it has received commitments from institutional investors to purchase ... common stock in an at-the-market registered direct offering, led ... Company entered into definitive purchase agreements with these investors ...
(Date:1/15/2014)... , Jan. 15, 2014  Manufacturers, suppliers and distributors ... able to protect their most important business assets, ... ) Because of the highly-competitive ... remains one of the most litigious industry sectors ...
Breaking Medicine Technology:Mission Pharmacal Conducts Online Survey of Osteoporosis Patients 2Mission Pharmacal Conducts Online Survey of Osteoporosis Patients 3Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 2Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 3Intellectual Property Insurance for Medical-related Products and Services 2
... Phase III Studies With Ofatumumab, Zalutumumab and Zanolimumab, ... (OMX:,GEN) reports today that the last patient to ... in the pivotal Phase III clinical trial,of ofatumumab ... received the last scheduled treatment., In order ...
... Company to Host Conference Call/Webcast at 8:30 a.m. ... May 28 Alfacell Corporation,(Nasdaq: ACEL ) ... from its confirmatory Phase IIIb clinical trial of ... significance for the,primary endpoint of survival in unresectable ...
Cached Medicine Technology:Genmab Announces Updates on Phase III Cancer Studies 2Genmab Announces Updates on Phase III Cancer Studies 3Alfacell Corporation Announces Preliminary Results From ONCONASE(R) Phase IIIb Clinical Trial 2Alfacell Corporation Announces Preliminary Results From ONCONASE(R) Phase IIIb Clinical Trial 3Alfacell Corporation Announces Preliminary Results From ONCONASE(R) Phase IIIb Clinical Trial 4Alfacell Corporation Announces Preliminary Results From ONCONASE(R) Phase IIIb Clinical Trial 5
(Date:7/9/2014)... innovative tool that captures heretofore hidden ways that cells ... protein that makes breast cancer cells more likely to ... cancer,s spread in part by blocking two other proteins ... suggests these two disease processes could have unexpected ties. ... 10 issue of Nature , points to the ...
(Date:7/9/2014)... Center paint a relatively optimistic picture of women,s chances ... spread to the chest wall or skin, but not ... regardless of size and whether they have involved lymph ... called "locally advanced" tumors, suggesting that they are a ... Locally advanced breast cancers of this and other types ...
(Date:7/9/2014)... The Miriam Hospital have found that people with ... depressed have difficulty sticking to a pulmonary rehabilitation ... women, and screening and brief treatment of depression ... study and its findings are published in print ... obstructive pulmonary disease is a common and often ...
(Date:7/9/2014)... has been a sharp increase in the number of ... the online, interactive service that allows patients to view ... schedule appointments, and renew prescriptions. , Over a six-year ... each year increased five-fold, while the number of ... to a study by Dr. David Gerber , ...
(Date:7/9/2014)... p>YouTube is for more than watching World Cup highlights, ... of skateboarders landing in unfortunate positions on railings. A ... Dermatology Online Journal shows that YouTube also ... with the public on topics of skin cancer and ... media is the future of how we communicate around ...
Breaking Medicine News(10 mins):Health News:Protein pushes breast cancer cells to metastasize 2Health News:Protein pushes breast cancer cells to metastasize 3Health News:Fox Chase researchers recommend updating the staging criteria for breast cancer diagnoses 2Health News:Fox Chase researchers recommend updating the staging criteria for breast cancer diagnoses 3Health News:Miriam Hospital study examines effect of depressed mood on pulmonary rehab completion 2Health News:MyChart use skyrocketing among cancer patients, UT Southwestern study finds 2Health News:MyChart use skyrocketing among cancer patients, UT Southwestern study finds 3Health News:Study of dermatology on YouTube shows new ways science reaches public 2
... a procedure wherein healthy cartilage is transplanted to fix ... OATS procedure) is superior to the standard of care ... such lesions may ultimately help to prevent the onset ... activities reliably. The study by Hospital for Special Surgery ...
... Climate change has impacts on forests, fields, rivers -- and ... these impacts more accurately, a comprehensive comparison of computer-based simulations ... the first time, sectors ranging from ecosystems to agriculture to ... framework. , The models will be provided by more than ...
... HealthDay Reporter , MONDAY, Feb. 6 (HealthDay News) -- Women ... be at increased risk of readmission to a psychiatric hospital ... study suggests. The findings, which appear in the February ... several previous studies showing that women who undergo abortion do ...
... MONDAY, Feb. 6 (HealthDay News) -- Treatment with three ... slightly increased risk of death, a new analysis suggests. ... taken into account by doctors and patients, according to ... analyzed the findings of 10 clinical trials that included ...
... 2012 -- The Fogarty Institute for Innovation announced ... Training Fellowship. This unique, year-long clinical training program ... will provide Fellows with broad exposure to ... emphasis on interventional training. Fellows will also engage ...
... genetics has been peeled back. A team of researchers ... Richard G. Pestell, M.D., PhD., FACP, Director of the KCC ... shown in a study published online Feb. 6 in the Journal ... genetic breakdown known as chromosomal instability (CIN). CIN is a known, ...
Cached Medicine News:Health News:New procedure bests standard of care for fixing damaged cartilage 2Health News:New procedure bests standard of care for fixing damaged cartilage 3Health News:Quantifying climate impacts: New comprehensive model comparison launched 2Health News:Quantifying climate impacts: New comprehensive model comparison launched 3Health News:Does Abortion in First Trimester Raise Risk of Mental Ills' Return? 2Health News:Does Abortion in First Trimester Raise Risk of Mental Ills' Return? 3Health News:Certain Cancer Drugs May Have Fatal Side Effects: Analysis 2Health News:Fogarty Institute for Innovation launches advanced endovascular training fellowship 2Health News:Drugs targeting chromosomal instability may fight a particular breast cancer subtype 2Health News:Drugs targeting chromosomal instability may fight a particular breast cancer subtype 3